A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...

Biomarker testing is vital for all patients with lung cancer, especially younger individuals who have higher rates of ...

The FDA cleared the investigational new drug application of IDE849, a potential first-in-class DLL3-targeted antibody-drug ...

The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

Small-cell lung cancer (SCLC) is one of the most aggressive and deadly types of cancer, often linked to smoking. Although it ...

A team of researchers has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings may help improve future ways to deliver ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...